What is HC Wainwright’s Estimate for DTIL FY2026 Earnings?

Precision BioSciences, Inc. (NASDAQ:DTIL) – Research analysts at HC Wainwright raised their FY2026 earnings estimates for shares of Precision BioSciences in a note issued to investors on Thursday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($2.01) per share for the year, up from their prior estimate of ($3.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.41) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at $1.13 EPS.

Several other research firms also recently issued reports on DTIL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precision BioSciences in a report on Tuesday, November 3rd. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Precision BioSciences has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Precision BioSciences Stock Down 8.7%

Shares of NASDAQ DTIL opened at $9.68 on Monday. The business has a fifty day simple moving average of $6.93 and a 200 day simple moving average of $6.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 12.82 and a current ratio of 10.47. Precision BioSciences has a one year low of $3.53 and a one year high of $11.29.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.57. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 56.69%.

Institutional Trading of Precision BioSciences

A number of institutional investors have recently modified their holdings of DTIL. Quantinno Capital Management LP bought a new stake in shares of Precision BioSciences in the 1st quarter valued at about $104,000. Bank of America Corp DE raised its position in shares of Precision BioSciences by 167.6% during the first quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after acquiring an additional 17,172 shares during the last quarter. Engineers Gate Manager LP acquired a new position in shares of Precision BioSciences in the second quarter worth approximately $164,000. Bank of New York Mellon Corp acquired a new position in shares of Precision BioSciences in the second quarter worth approximately $467,000. Finally, Russell Investments Group Ltd. boosted its holdings in Precision BioSciences by 4,217.9% in the third quarter. Russell Investments Group Ltd. now owns 82,818 shares of the company’s stock valued at $518,000 after acquiring an additional 80,900 shares during the last quarter. 37.99% of the stock is currently owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.